Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of autologous stem-cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.